CC
ASMB icon

Commodore Capital’s Assembly Biosciences ASMB Stock Holding History

Commodore Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.8M Hold
1,000,000
– – 1.61% 21
2025
Q4 		$34M Hold
1,000,000
– – 2.26% 18
2025
Q3 		$25.6M Buy
+1,000,000
New +$21.9M 1.25% 25

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Commodore Capital's ASMB Position: Q1 2026 in Review

Commodore Capital held its Assembly Biosciences (ASMB) position steady in Q1 2026 at 1,000,000 shares worth $27.8M. The position accounts for 1.61% of the portfolio, ranked #21.

Commodore Capital first reported a position in ASMB in Q3 2025 and has held it in 3 quarters since. The position peaked at $34M in Q4 2025. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Commodore Capital held 1,000,000 shares of Assembly Biosciences worth $27.8M as of Q1 2026.
  • Commodore Capital left its Assembly Biosciences share count unchanged in Q1 2026.
  • Assembly Biosciences made up 1.61% of Commodore Capital's portfolio in Q1 2026, its #21 holding.
  • Commodore Capital first reported a position in Assembly Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Commodore Capital's Assembly Biosciences position peaked at $34M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Commodore Capital's 13F filing for Q1 2026, filed 15 May 2026.